Benefit-risk assessment of the TNF-antagonists adalimumab and certolizumab pegol for maintenance treatment of Crohn's disease: P-35.


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles